1. Home
  2. Directory
  3. Washington
  4. Seattle
  5. Internal Medicine
  6. NPI Profile
  7. Prescriptions 1720171937

DR. REBECCA KRUSE-JARRES M.D.
Prescription History 1720171937
Internal Medicine - Hematology & Oncology in Seattle, WA

NPI Status: Active since October 02, 2006

Contact Information

701 PIKE ST STE 1900
SEATTLE, WA
ZIP 98101
Phone: (206) 614-1128
Fax: (206) 614-1170

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. REBECCA KRUSE-JARRES M.D., an active Hematology & Oncology specialist practicing in Seattle, WA. Our medical registry currently tracks 3 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 43 documented patient claims. Among these therapy options, the most frequently utilized medication is Tranexamic Acid, which accounts for 20 claims alone.

Medication Index

C
O
T
No matching medications currently found on file.

Celecoxib

Generic Formulation: CelecoxibSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 11
30-Day Fills 21.0
Days Supply 610
WA State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,250
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 57.7% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $151.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$13.77

State Avg Cost Per Claim

$52.44

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pyrazole derivative and selective CYCLOOXYGENASE 2 INHIBITOR that is used to treat symptoms associated with RHEUMATOID ARTHRITIS; OSTEOARTHRITIS and JUVENILE ARTHRITIS, as well as the management of ACUTE PAIN.

Therapeutic Applications

This medication is a nonsteroidal anti-inflammatory drug (NSAID), specifically a COX-2 inhibitor, which relieves pain and swelling (inflammation). It is used to treat arthritis, acute pain, and menstrual pain and discomfort. The pain and swelling relief provided by this medication helps you perform more of your normal daily activities. If you are treating a chronic condition such as arthritis, ask your doctor about non-drug treatments and/or using other medications to treat your pain. See also Warning section. This drug works by blocking the enzyme in your body that makes prostaglandins. Decreasing prostaglandins helps to reduce pain and swelling.

Oxycodone Hcl

Generic Formulation: Oxycodone HclSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 157
WA State Average Benchmarks
Peer Average Claims49.0
Peer Average 30-Day Fills50.1
Peer Average Days Supply920
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 75.5% less volume than the regional standard for practitioners inside WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $89.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$7.42

State Avg Cost Per Claim

$21.32

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semisynthetic derivative of CODEINE.

Therapeutic Applications

This medication is used to help relieve moderate to severe pain. Oxycodone belongs to a class of drugs known as opioid analgesics. It works in the brain to change how your body feels and responds to pain.

Tranexamic Acid

Generic Formulation: Tranexamic AcidSpecialty: Hematology-Oncology
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 162
WA State Average Benchmarks
Peer Average Claims13.0
Peer Average 30-Day Fills13.3
Peer Average Days Supply133
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 53.8% higher than the standard regional baseline profile for WA. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,214.22 across this reporting matrix range.

Provider Avg Cost Per Claim

$110.71

State Avg Cost Per Claim

$72.23

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

Antifibrinolytic hemostatic used in severe hemorrhage.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. REBECCA KRUSE-JARRES M.D. provides transparency into local medical care patterns within Seattle, WA.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Hematology & Oncology** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.